Emily M. Leproust Sells 1,487 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Free Report) CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total value of $55,658.41. Following the transaction, the chief executive officer now directly owns 516,409 shares in the company, valued at approximately $19,329,188.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Twist Bioscience Stock Performance

Shares of TWST opened at $37.57 on Friday. The stock’s fifty day moving average price is $36.60 and its two-hundred day moving average price is $27.60. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.03. The firm had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The business’s revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.74) earnings per share. As a group, analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on TWST. Barclays lifted their target price on Twist Bioscience from $30.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Finally, Scotiabank lifted their target price on Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research report on Monday, February 5th.

Read Our Latest Stock Analysis on TWST

Institutional Trading of Twist Bioscience

Hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors raised its stake in shares of Twist Bioscience by 101.3% in the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after buying an additional 382 shares during the period. Federated Hermes Inc. purchased a new position in shares of Twist Bioscience in the third quarter valued at $29,000. China Universal Asset Management Co. Ltd. grew its position in shares of Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $30,000. Finally, KBC Group NV purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $42,000.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Further Reading

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.